Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAYLOAD: RRx-001 + Irinotecan in Advanced Solid Tumors
NCT02801097Phase 1Terminated
- Sponsor
- EpicentRx
- Start
- Aug 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Nibrozetone in solid tumor and metastatic cancer, sponsored by EpicentRx. Primary endpoint: Number, frequency and type of adverse events at 14 weeks. Started Aug 2016; status: terminated.
02
Drugs
Nibrozetone
03
Conditions
solid tumormetastatic cancer
Beyond the preview
Go deeper on NCT02801097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02801097.